These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 18516813)

  • 1. Rotigotine: Parkinson's disease: a step backward.
    Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease.
    Chatsis V
    Issues Emerg Health Technol; 2008 Feb; (112):1-6. PubMed ID: 18354859
    [No Abstract]   [Full Text] [Related]  

  • 3. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal rotigotine (Neupro) for Parkinson's disease.
    Med Lett Drugs Ther; 2007 Aug; 49(1268):69-70. PubMed ID: 17712291
    [No Abstract]   [Full Text] [Related]  

  • 5. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
    Sanford M; Scott LJ
    CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on rotigotine in Parkinson's disease.
    Baldwin CM; Keating GM
    Drugs Aging; 2008; 25(2):175-7. PubMed ID: 18257604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug safety evaluation of rotigotine.
    Sprenger FS; Seppi K; Poewe W
    Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
    Naidu Y; Chaudhuri KR
    Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dopamine receptor agonists: new forms and new possibilities in the treatment of Parkinson's disease].
    Katunina EA; Titova NV; Bezdolny YN; Shykkerimov RK; Gasanov MG; Burd SG; Lebedeva AV; Boiko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(5):34-40. PubMed ID: 26356158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome.
    Kenney C; Jankovic J
    Expert Opin Pharmacother; 2007 Jun; 8(9):1329-35. PubMed ID: 17563266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview.
    Zesiewicz TA; Martinez-Martin P
    Expert Rev Neurother; 2013 Dec; 13(12):1329-42. PubMed ID: 24236902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
    Perez-Lloret S; Rey MV; Ratti PL; Rascol O
    Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rotigotine transdermal system for the treatment of Parkinson's disease.
    Pham DQ; Nogid A
    Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled trial of rotigotine monotherapy in early Parkinson's disease.
    Parkinson Study Group
    Arch Neurol; 2003 Dec; 60(12):1721-8. PubMed ID: 14676046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
    Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
    Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
    Baldwin CM; Keating GM
    CNS Drugs; 2007; 21(12):1039-55. PubMed ID: 18020483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
    Metman LV; Gillespie M; Farmer C; Bibbiani F; Konitsiotis S; Morris M; Shill H; Bara-Jimenez W; Mouradian MM; Chase TN
    Clin Neuropharmacol; 2001; 24(3):163-9. PubMed ID: 11391128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.